Urge Congress to Provide More Funding for Cancer Research in Fiscal Year 2023

April 26, 2022

The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support for cancer research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) are vital in our nation’s efforts to combat and ultimately cure diseases like cancer.

For fiscal year (FY) 2023, ASCO is asking Congress to provide $49 billion for the NIH, which is an increase of $4.1 billion from FY 2022. Additionally, ASCO supports the NCI’s budget request to Congress for $7.76 billion for the NCI, an increase of $853 million from FY 2022, which includes $216 million for the final year of the original Cancer Moonshot Initiative.

On May 11, the Association sent testimony to a Senate subcommittee detailing recommendations on NIH and NCI funding. ASCO cited that a strong commitment to scientific discovery will help the research community continue current momentum and sustain the nation’s position as the world leader in biomedical research.

Cancer research funded by the NIH and NCI has led to significant advances in cancer prevention, detection, diagnosis, treatment, and quality of life for patients, leading to nearly 17 million survivors of cancer living in the United States today. Much of the nation’s oncology research is federally funded – and these trials are the primary drivers in the development of new cancer therapies, including rare and pediatric cancers.

Urge Congress to support increased funding for cancer research in FY 2023.

Advanced Research Projects Agency for Health (ARPA-H)

ASCO is eager to work with Congress and the Administration on the establishment of the Advanced Research Projects Agency for Health (ARPA-H), the proposed new biomedical research agency focused on high-risk, bold, translational research projects. ARPA-H has the potential to accelerate progress against diseases like cancer, however, the Association cautions that any investment in ARPA-H should not come at the expense of robust and sustained increases for the NIH and NCI. Read ASCO’s March 2022 statement on the President’s FY 2023 budget and our principles for the development of ARPA-H.

This page will be updated throughout the year with new ways to support advocacy efforts and updates on ASCO’s activities in support of federal research funding.

Join the ASCO ACT Network to stay current on advocacy opportunities.